Sign up to save your podcasts
Or
Share Auditing the Telomere Cliff
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Auditing the Telomere Cliff
**Auditing the Telomere Cliff** Join Marcus and Katie as they initiate the TELOMERE CLIFF Archive, dissecting BioAge Labs' ambitious Q1 2026 public offering and the unsettling implications for the future of human longevity. Marcus, ever the cynic, labels BioAge's $115 million venture a "biological payday loan," questioning the transparency of their finances and the true cost of delaying inevitable decay. Katie, with her clinical precision, presents the data on Azelaprag (BGE-102) and its purported 86% reduction in inflammatory markers, but even her meticulously sourced figures can't mask the boardroom intrigue and alleged manipulation of forecasts following a terminated trial. The audit quickly unearths a troubling past: BioAge's Azelaprag, initially hailed as an "exercise mimetic," was halted due to severe hepatic toxicity—a "Senolytic Insolvency" event that threatened to "accelerate the exit" rather than extend life. As BioAge pivots to BGE-102, targeting the NLRP3 inflammasome, Marcus challenges the "AI-driven centenarian model" as mere "survivorship bias," a statistical parlor trick designed to ignore those who didn't make it. The conversation escalates, touching upon the widespread use of GLP-1 analogues, where Katie reveals a shocking truth: patients are losing up to forty percent of their lean muscle mass, consuming their "structural beams" in pursuit of a smaller number on the scale. As the data points to a $334.5 million "temporary deferral of biological insolvency," Marcus's own biology begins to betray him. A persistent tremor in his hands—a ghost from a past attempt to calibrate a "methylation clock"—becomes a visceral manifestation of the decay they are auditing. Katie, for a rare moment, drops her clinical mask, acknowledging Marcus's personal struggle, linking his "jitter" to the market's own blind spots. In this chilling exchange, the cold calculus of corporate finance meets the intimate, unforgiving reality of cellular bankruptcy, leaving listeners to ponder: when the promise of youth comes at such a steep biological price, what exactly are we paying for?
View all episodes
By The Architect**Auditing the Telomere Cliff** Join Marcus and Katie as they initiate the TELOMERE CLIFF Archive, dissecting BioAge Labs' ambitious Q1 2026 public offering and the unsettling implications for the future of human longevity. Marcus, ever the cynic, labels BioAge's $115 million venture a "biological payday loan," questioning the transparency of their finances and the true cost of delaying inevitable decay. Katie, with her clinical precision, presents the data on Azelaprag (BGE-102) and its purported 86% reduction in inflammatory markers, but even her meticulously sourced figures can't mask the boardroom intrigue and alleged manipulation of forecasts following a terminated trial. The audit quickly unearths a troubling past: BioAge's Azelaprag, initially hailed as an "exercise mimetic," was halted due to severe hepatic toxicity—a "Senolytic Insolvency" event that threatened to "accelerate the exit" rather than extend life. As BioAge pivots to BGE-102, targeting the NLRP3 inflammasome, Marcus challenges the "AI-driven centenarian model" as mere "survivorship bias," a statistical parlor trick designed to ignore those who didn't make it. The conversation escalates, touching upon the widespread use of GLP-1 analogues, where Katie reveals a shocking truth: patients are losing up to forty percent of their lean muscle mass, consuming their "structural beams" in pursuit of a smaller number on the scale. As the data points to a $334.5 million "temporary deferral of biological insolvency," Marcus's own biology begins to betray him. A persistent tremor in his hands—a ghost from a past attempt to calibrate a "methylation clock"—becomes a visceral manifestation of the decay they are auditing. Katie, for a rare moment, drops her clinical mask, acknowledging Marcus's personal struggle, linking his "jitter" to the market's own blind spots. In this chilling exchange, the cold calculus of corporate finance meets the intimate, unforgiving reality of cellular bankruptcy, leaving listeners to ponder: when the promise of youth comes at such a steep biological price, what exactly are we paying for?